SOHO 2014 Slide Gallery

slide galleryPresentation slides are made available after the Society of Hematologic Oncology Annual Meeting has concluded. Below you will find a listing of speakers and slides that you may view at your leisure. Click the link on the speakers name to go to the slide presentation.

Feel free to download slides that interest you. Please note that some speakers choose not to share their presentations. If this is the case, you will see an image with “Slides Not Available”.

Videos of each presentation will be posted following CME approval.

Wednesday, September 17, 2014
Session I: Acute Lymphoblastic Leukemia
• How I Treat Young Adults with ALL Wendy Stock, MD
• Novel Immunotherapeutic Strategies: ALL-Directed Antibodies Dan J. Deangelo, MD, PhD
• Is Transplantation Still the Standard of Care in Ph Pos ALL? Deborah A. Thomas, MD
• Minimal Residual Disease and Allogeneic Transplantation in ALL─Who Benefits? Anthony H. Goldstone, FRCR, (M)
• Current Impact of Next Generation Sequencing in the Management of ALL Ching-Hon Pui, MD
• ALL in the Elderly Nicola Gökbuget, MD
• Oral Abstract #111: Characterization of New Cryptic Rearrangements of the
Erythropoietin Receptor in Ph-Like Acute Lymphoblastic Leukemia
Ilaria Iacobucci, PhD
Box Lunch Session I
• Genetics, Genomics and Pharmacogenomics in Hematologic Malignancies for the Advanced Oncology Nurse Courtney DiNardo, MD
Plenary Session I
• Keynote Speaker: CAR T-Cell Therapy of B-Cell Cancers
Recipient of the 2014 Distinguished Lecturer Award
Renier Brentjens, MD, PhD
Session II: Chronic Lymphocytic Leukemia
• “How I Treat my Patients with CLL” Michael J. Keating, MB, BS
• Immune dysregulation in CLL: How to Manage Thrombocytopenias and Infections Federico Caligaris-Cappio, MD
• Is BCL2 Inhibition Coming Along? Andrew W. Roberts, MD
• “Old” inhibitors: Ibrutinib and Idelalisib: Where are We Standing? Susan O’Brien, MD
• Richter’s Syndrome: From Biology to Treatment Nitin Jain, MD
• Novel Treatments for CLL Thomas J. Kipps, MD, PhD
• Debate: Do we Still Need Stem Cell Transplantation with The Novel BcR Inhibitors?
Peter Dreger, MD
William G. Wierda, MD, PhD
• Oral Abstract #304: Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results from the Randomized Phase III
RESONATE™ (PCYC-1112) Trial
Jennifer R. Brown, MD, PhD
• Oral Abstract #308: Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients with CLL/SLL Susan O’Brien, MD
Thursday, September 18, 2014
Session III: Myeloproliferative Neoplasms
• How I Treat my Patients with MPNs Claire Harrison, MD
• Prognostic Factors for Thrombosis and Survival in ET and PV Revisited Francesco Passamonti, MD
• New Therapeutic Approaches in PV Srdan Verstovsek, MD, PhD
• How many Inhibitors for JAK2? Animesh Pardanani, MD
• Effect of JAK inhibitors on Timing and Conduct of Transplant in Uday R. Popat, MD
• Oral Abstract #705: To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors Kamal Menghrajani, MD
Session IV: Myelodysplastic Syndromes
• How I Treat my Patients with Lower-Risk MDS (including GF, Lenalidomide, HMAs) Alan F. List, MD
• Treatment of Lower Risk MDS that has Failed HMA and Lenalidomide Guillermo Garcia-Manero, MD
• Treatment of Higher Risk MDS Lionel Adès, MD, PhD
• Treatment of Higher Risk MDS–HMA Failure Rami S. Komrokji, MD
• What is the Role of Genomic Analysis in Our Daily MDS Practice? Rafael Bejar, MD, PhD
• Which Patients Should Undergo Allogeneic Stem Cell Transplant for MDS and When Should We Do It? Betul Oran, MD
• MDS/MPN Overlap Syndromes Eric Padron, MD
• Oral Abstract #601: A Third of Transfusion-Dependent Patients with Myelodysplastic Syndromes Develop Alloantibodies Against Red Blood Cell Antigens Uri Rozovski, MD
• Oral Abstract #603: Chromosomal 3 Abnormalities in MDS: Implications on Prognosis and Response to Treatment David Sallman, MD
• Debate: Should Molecular Determinants Govern your Decision for Transplant in MDS?
Corey S. Cutler, MD, MPH, FRCPC
Mohamed A. Kharfan-Dabaja, MD
Box Lunch Session II : Case Studies in Hematologic Malignancies
• CLL Case Study Alessandra Ferrajoli, MDit link
• Lymphoma Case Study Loretta Nastoupil, MD
• Transplant Case Study Richard Champlin, MD
• Myeloma Case Study Jatin J. Shah, MD
Plenary Session II
• Novel Molecular Genetics in AML Ross L. Levine, MD
Session V: Acute Myeloid Leukemia
• How I Treat my Patients with AML Selina M. Luger, MD
• Minimal Residual Disease in AML: Why Has it Lagged Behind Pediatric ALL? Elisabeth M. Paietta, MD
• Improving Outcome in the Already Favorable Core Binding Factor AMLs Alan K. Burnett, MD
• Innovative Strategies For Treatment of Relapsed AML Farhad Ravandi, MD
• AML in CR1—Who should get an allogeneic stem cell transplant and should we use an ablative or nonmyeloablative regimen? Richard Champlin, MD
• Has The Standard of Care in APL Changed? Martin S. Tallman, MD
• How Does the Discovery of Novel Molecular Genetics in AML Guide Treatment? Peter J. Valk, MD
• What’s New in Induction? Richard M. Stone, MD
• Intensive Induction Treatment for Elderly AML Meir Wetzler, MD, FACP
• Debate: Are Hypomethylating Agents the Standard of Care for Older
Adults with AML Not Candidates for Intensive Chemotherapy?
William G. Blum, MD
Elihu Estey, MD
• Oral Abstract #237: Outcome of FLT3 ITD Mutated AML Patients Based on Different Treatment Strategies Talha Badar MBBS, FCPS
• Oral Abstract #225: Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts Tapan M. Kadia, MD
• Oral Abstract #231: A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML) Aziz Nazha MD
Friday, September 19, 2014
Session VI: Chronic Myeloid Leukemia
• “How I Treat my Patients with CML” Jorge Cortés, MD
• Optimizing Frontline Therapy Timothy P. Hughes, MD, FRACP, FRCPA
• Prognosis and Molecular Monitoring Jerald P. Radich, MD
• Which TKI? Jorge Cortés, MD
• When, If Ever, Is It Safe To Stop Therapy? Timothy P. Hughes, MD, FRACP, FRCPA
• Management of Advanced Phase CML Elias Jabbour, MD
• Debate: The Long-Term Toxicity of Second Generation TKIs Precludes their
Widespread Use in Frontline Treatment of CML
Francisco Cervantes, MD, PhD
Jerald P. Radich, MD
• Oral Abstract #411: Targeting p53 in CML Chronic Phase Leukemia Stem Cells Luke F. Peterson, PhD
Session VII: Multiple Myeloma
• Is Genome Sequencing Useful In Multiple Myeloma A. Keith Stewart, MB, ChB
• Which Smoldering Myeloma Patients Should Be Treated Early? Sagar Lonial, MD
• Is MRD Assessment Ready for Primetime? Antonio Palumbo, MD
• Management of Younger Patients or Older Transplant Eligible Patients Robert Orlowski, MD, PhD
• Management of Frail or Older Myeloma Patients Antonio Palumbo, MD
• Management of High Risk Myeloma: Optimal Induction, Consolidation and Maintenance Sundar Jagannath, MD
• New Targets In Relapsed Myeloma Shaji K. Kumar, MD
• Debate: Is Myeloma Curable?
Bart Barlogie, MD, PhD
Jeffrey Wolf, MD
• Oral Abstract #804: Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response Muhamad Alhaj Moustafa, MD
Box Lunch Session III: Diffuse Large B Cell Lymphoma and Other Aggressive B Cell Lymphomas
• Is There Still a Role for Morphological Variants of DLBCL? Do We Still Need The Category of B Cell Lymphoma, Intermediate Between DLBCL and BL? L. Jeffrey Medeiros, MD
• A Practical Approach to “Double Hit Lymphoma” Pei Lin, MD
• Genomic Sequencing and Translocation of MYC Gene Impact Diagnosis, Differential Diagnosis and Risk Stratification in DLBCL and Burkitt Lymphoma Ken H. Young, MD, PhD
Plenary Session III
• CARs Therapy in B Cell Malignancies Noelle Frey, MD
Session VIII: Lymphoma
• “How I Treat my Patients with Lymphoma” Myc+ DLBCL Wyndham Wilson, MD
• Cell of Origin and Beyond: Is R-CHOP No Longer a One Size Fits All Approach for DLBCL Paul A. Hamlin, MD
• How Do I Choose a Front-Line Therapy In Follicular Lymphoma? Maria Alma Rodriguez, MD
• R2, Ibrutinib & Idelalisib in Relapsed Lymphoma: A Practical Guide To Who, What, Where, When, and For How Long? Loretta Nastoupil, MD
• The Role of Chemotherapy Alone for Early Stage Hodgkin Lymphoma Kerry Savage, MD
• Managing Primary and Secondary CNS Lymphomas Tracy T. Batchelor, MD, MPH
• Newly Diagnosed PTCL: Choosing An Initial Approach Steven M. Horwitz, MD
• Allogeneic Stem Cell Transplantation for NHL: Who Should and Who Should Not be Referred David G. Maloney, MD, PhD
• Lymphoma 2014: Ongoing, Potentially Practice Changing Clinical Trials You and Your Patients Should Know About Jeremy S. Abramson, MD
• Molecular Monitoring Lymphoma Patients Post-Therapy: If We Are Scanning Less, What Else Can We do? Mark J. Roschewski, MD
• Debate: Topic Mantle Cell Lymphoma: Fit Patients Should Get High Dose Therapy and Autologous Stem Cell in CR1
Leo I. Gordon, MD
Michael E. Williams, MD
• Oral Abstract #504: Development of a novel humanized anti-CD20 chimeric antigen receptor; Effect on the CD20 down-regulated and mAb therapy resistant tumor cells Keisuke Watanabe, MD
• Oral Abstract #516: Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Lijuan Deng, MD
Saturday, September 20, 2014
Session IX: Research Topics
• Immunotherapy Katy Rezvani, MD, PhD
• Stem Cell Origin of MPN Disease Initiation Radek C. Skoda, MD
• Strategies to Target the Leukemic Stem Cell in CML and PH+ B-ALL Richard A. Van Etten, MD, PhD
• Targeting the Leukemia Stem Cell Microenvironment Michael Andreeff, MD, PhD
• Genomic Studies of Mature T-cell Lymphoma/Leukemia Megan S. Lim, MD
• Targeting Kinome in Leukemia: Becoming Clinical Reality Marina Y. Konopleva, MD, PhD
• Oral Abstract #206: Tumor Suppressor Role for B55 alpha PP2A Isoform in AML Peter Ruvolo, PhD
• Oral Abstract #703: Mutational Profiling of JAK2V617F vs. CALR mutated Primary Myelofibrosis Fabio Santos, MD
• Oral Abstract #232: Next generation sequencing-based monitoring for minimal residual disease in AML Chi Young Ok, MD
Session X: Conference Highlights and Future Directions
• Acute Leukemias Hagop Kantarjian, MD
• Myeloproliferative Neoplasms Srdan Verstovsek, MD, PhD
• Chronic Lymphocytic Leukemia Michael J. Keating, MB, BS
• Chronic Myelogenous Leukemia Elias Jabbour, MD
• Multiple Myeloma Sagar Lonial, MD
• Research Topics Michael Andreeff, MD, PhD